Histone deacetylase inhibitors in multiple myeloma

Histone deacetylase inhibitors in multiple myeloma

Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-enviro...

Full description

Bibliographic Details
Main Authors:	Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken
Format:	Article
Language:	English
Published:	PAGEPress Publications 2009-06-01
Series:	Hematology Reports
Online Access:	http://www.pagepress.org/journals/index.php/hr/article/view/49

Similar Items

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
by: Jinsong Hu, et al.
Published: (2012-11-01)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
by: Elke De Bruyne, et al.
Published: (2013-04-01)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
by: Liesbeth Bieghs, et al.
Published: (2010-01-01)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
by: Tandon N, et al.
Published: (2016-05-01)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
by: Kim De Veirman, et al.
Published: (2014-06-01)

Histone deacetylase inhibitors : mode of inhibition and histone deacetylase phosphorylation
by: Sekhavat, Anoushe
Published: (2013)

Histone deacetylase inhibitors : mode of inhibition and histone deacetylase phosphorylation
by: Sekhavat, Anoushe
Published: (2013)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
by: Seiichi Okabe, et al.
Published: (2021-03-01)

Histone deacetylase inhibitors
by: Marzena Baran, et al.
Published: (2020-08-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
by: Masumeh Sanaei, et al.
Published: (2019-01-01)

Synthesis of inhibitors of histone deacetylase
by: Dines, J.
Published: (2008)

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.
by: Song Xu, et al.
Published: (2013-01-01)

Medicinal chemistry of histone deacetylase inhibitors
by: Ružić Dušan, et al.
Published: (2021-01-01)

Clinical Toxicities of Histone Deacetylase Inhibitors
by: Richard L. Piekarz, et al.
Published: (2010-08-01)

The application of histone deacetylases inhibitors in glioblastoma
by: Rui Chen, et al.
Published: (2020-07-01)

Histone Deacetylase Inhibitors as Anticancer Drugs
by: Tomas Eckschlager, et al.
Published: (2017-07-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
by: Madeleine S. Q. Kortenhorst, et al.
Published: (2006-01-01)

Histone Deacetylases and their Inhibitors in Cancer Epigenetics
by: Kelly N. Hassell
Published: (2019-11-01)

Mechanistic analysis of histone deacetylase inhibitors
by: Fotheringham, Susan
Published: (2007)

Antidepressant Actions of Histone Deacetylase Inhibitors
by: Haggarty, Stephen J., et al.
Published: (2010)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
by: Sylvia Faict, et al.
Published: (2019-11-01)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
by: Ya-Li Yao, et al.
Published: (2011-01-01)

Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX
by: Lynda Ekou, et al.
Published: (2011-01-01)

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
by: Anna Wawruszak, et al.
Published: (2019-01-01)

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
by: Haneen Nur, et al.
Published: (2013-01-01)

Histone deacetylases in stroke
by: Mei-Han Kao, et al.
Published: (2019-01-01)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
by: Elisabetta Mattioli, et al.
Published: (2019-01-01)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
by: Kim Freese, et al.
Published: (2019-10-01)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
by: Redic KA, et al.
Published: (2016-05-01)

The therapeutic role of histone deacetylase inhibitors in keloids
by: Kwan Yau Chan, et al.
Published: (2018)

Histone Deacetylase Inhibitors from Marine Invertebrates
by: Claudio Luparello, et al.
Published: (2020-11-01)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
by: Guo Li, et al.
Published: (2020-09-01)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
by: Flávia Alves Verza, et al.
Published: (2020-06-01)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
by: H. Miles Prince, et al.
Published: (2010-08-01)

Attenuation of choroidal neovascularization by histone deacetylase inhibitor.
by: Nymph Chan, et al.
Published: (2015-01-01)

Zinc binding groups for histone deacetylase inhibitors
by: Lei Zhang, et al.
Published: (2018-01-01)

The effect of histone deacetylase inhibitors on AHSP expression.
by: Mohammad Ali Okhovat, et al.
Published: (2018-01-01)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
by: Mitchell J. Hadden, et al.
Published: (2018-09-01)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
by: Sebastian Stintzing, et al.
Published: (2011-01-01)